Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Poly ADP Ribose Polymerase (PARP) Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 0 results

Not applicableUnknownNCT05310370
What this trial is testing

HRD and Resistance to PAPPi in EOC Patients

Who this might be right for
Epithelial Ovarian CancerHomologous Recombination DeficiencyHomologous Recombination Repair Gene Mutation+4 more
Lei Li 400
Testing effectiveness (Phase 2)Looking for participantsNCT06525298
What this trial is testing

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Who this might be right for
Advanced Solid TumorHomologous Recombination DeficiencyHRR Deficiency
Eisbach Bio GmbH 144
Testing effectiveness (Phase 2)Active Not RecruitingNCT03368729
What this trial is testing

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 Positive Breast Carcinoma
University of Alabama at Birmingham 46
Testing effectiveness (Phase 2)WithdrawnNCT01244009
What this trial is testing

MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Who this might be right for
LymphomaMantle-Cell
Tesaro, Inc.
Not applicableUnknownNCT05044091
What this trial is testing

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Who this might be right for
Ovarian CancerHRDPARP Inhibitor
Xiaoxiang Chen 100
Testing effectiveness (Phase 2)Looking for participantsNCT05898399
What this trial is testing

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Who this might be right for
Advanced Solid TumorMetastatic Solid Tumor
Artios Pharma Ltd 181
Testing effectiveness (Phase 2)Ended earlyNCT03330405
What this trial is testing

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Who this might be right for
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Pfizer 223
Testing effectiveness (Phase 2)Study completedNCT06433219
What this trial is testing

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Who this might be right for
Ovarian Cancer
EMD Serono Research & Development Institute, Inc. 63
Large-scale testing (Phase 3)Active Not RecruitingNCT02655016
What this trial is testing

Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 733
Testing effectiveness (Phase 2)Study completedNCT04740190
What this trial is testing

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

Who this might be right for
Recurrent GliomaRecurrent GlioblastomaPoly ADP Ribose Polymerase (PARP) Inhibitor+2 more
The University of Hong Kong 33
Testing effectiveness (Phase 2)Study completedNCT05751629
What this trial is testing

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Neoplasm
Tesaro, Inc. 41
Large-scale testing (Phase 3)Looking for participantsNCT07472140
What this trial is testing

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancersPrimary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre 120
Testing effectiveness (Phase 2)Study completedNCT01051596
What this trial is testing

ABT-888 in Combination With Temozolomide for Colorectal Cancer

Who this might be right for
Colorectal Cancer
Georgetown University 75
Testing effectiveness (Phase 2)Ended earlyNCT05286827
What this trial is testing

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Who this might be right for
Pancreatic Acinar Cell Carcinoma
National Cancer Institute (NCI) 5
Early research (Phase 1)Study completedNCT00994071
What this trial is testing

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Who this might be right for
MedulloblastomaPontine GliomaEpendymoma+2 more
National Cancer Institute (NCI) 9
Early research (Phase 1)WithdrawnNCT04149145
What this trial is testing

Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer Recurrent
University of Alabama at Birmingham
Early research (Phase 1)Study completedNCT01009190
What this trial is testing

Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

Who this might be right for
Advanced Solid Tumors
pharmaand GmbH 85
Early research (Phase 1)Study completedNCT00387608
What this trial is testing

ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer

Who this might be right for
LeukemiaLymphomaUnspecified Adult Solid Tumor, Protocol Specific
National Institutes of Health Clinical Center (CC) 23